基本情報
- CAS
462-58-8- 標準SMILES
C[N+](C)(C)CCOC(N)=O- InChIKey
VPJXQGSRWJZDOB-UHFFFAOYSA-O- 分子式
- C6H15N2O2+
- 平均分子量
- 147.2 g/mol
- 単同位体質量
- 147.11335273
概要
Carbamoylcholine, also known as carbachol, is a muscarinic agonist discovered in 1932. Carbamoylcholine was initially used as a treatment for migraines, induction of diuresis, and other parasympathetic effects. Carbamoylcholine was granted FDA approval on 28 September 1972.
名称と識別子
- 優先名称
- Carbamylcholine
- IUPAC
- 2-carbamoyloxyethyl(trimethyl)azanium
- 現地名
- N,N,N-トリメチル-2-(カルバモイルオキシ)エタンアミニウム
- 英語名
- N,N,N-Trimethyl-2-(carbamoyloxy)ethanaminium
- 分子式
- C6H15N2O2
- 分子量
- 0
名称と別名
CarbamylcholineCarbamoylcholine462-58-8choline carbamate54Z8M50D6QEthanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-DTXSID0048397RefChem:54708DTXCID50283702-(trimethylazaniumyl)ethyl carbamate2-(carbamoyloxy)-N,N,N-trimethylethanaminium2-carbamoyloxyethyl(trimethyl)azanium
名称をさらに表示
(2-カルバモイルオキシエチル)トリメチルアミニウム2-(カルバモイルオキシ)-N,N,N-トリメチルエタンアミニウム2-[(アミノカルボニル)オキシ]-N,N,N-トリメチルエタンアミニウム[2-(アミノカルボニルオキシ)エチル]トリメチルアミニウムN,N,N-トリメチル-2-[(アミノカルボニル)オキシ]エタンアミニウムカルバモイルコリンコリンカルバマートカルバミルコリンN,N,N-トリメチル-2-(カルバモイルオキシ)エタンアミニウムN,N,N-トリメチル-2-[アミノカルボニルオキシ]エタンアミニウムO-カルバモイルコリン2-(トリメチルアザニウミル)エチル カルバマートN,N,N-Trimethyl-2-(carbamoyloxy)ethanaminium
2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminium2-[(AMINOCARBONYL)OXY]-N,N,N-TRIMETHYLETHANAMINIUM(2-Carbamoyloxy-ethyl)-trimethyl-ammoniumCHEMBL14CARBAMYL-CHOLINE(carbachol)(2-Carbamoyloxy-ethyl)-trimethyl-ammoniumCholine, carbonate (ester)CCE
物性
構造計算による物性
- XLogP
- -0.4
- 極性表面積
- 52.3 Ų
- 水素結合供与体数
- 1
- 水素結合受容体数
- 2
- 回転可能結合数
- 4
- 重原子数
- 10
- 形式電荷
- 1
- 複雑度
- 117
実験および物理化学的性質
DrugsPharmaceuticals -> Listed in ZINC15
LogP-3.78
Solubility9.48e-01 g/L
Human DrugsPharmaceuticals
Melting Point
208-210
210 °C
Physical DescriptionSolid
化学と産業
薬理情報
Protein BindingData regarding protein binding of carbamoylcholine is not readily available.
Pharmacodynamics
Carbamoylcholine is a parasympathomimetic that acts as an agonist of muscarinic and nicotinic receptors. It is more resistant to hydrolysis by acetylcholinesterase than other choline esters leading to a longer duration of action, with significant effects 24 hours after administration. Data regarding the therapeutic index of carbamoylcholine is not readily available. Patients should be counselled regarding the risk of administering the drug to patients with acute cardiac failure, bronchial asthma, peptic ulcer, hyperthyroidism, gastrointestinal spasm, urinary tract obstruction, or Parkinson's disease.
Mechanism of ActionCarbamoylcholine is a parasympathomimetic that acts as an agonist of muscarinic and nicotinic receptors. Intraocular administration leads to miosis and decreases intraocular pressure via increased aqueous humour outflow.
Biological Half-LifeData regarding the half life of carbamoylcholine is not readily available.
Metabolism/MetabolitesThe metabolism of carbamoylcholine has not been well described in the literature. It is metabolized to a small extent by acetylcholinesterase.
FDA Pharmacological Classification
54Z8M50D6Q
CARBAMOYLCHOLINE
Mechanisms of Action [MoA] - Cholinergic Agonists
Established Pharmacologic Class [EPC] - Cholinergic Receptor Agonist
Carbamoylcholine is a Cholinergic Receptor Agonist. The mechanism of action of carbamoylcholine is as a Cholinergic Agonist.
MeSH Pharmacological Classification
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).
関連反応
0 件
現在のフィルター条件では反応記録がありません。
化合物ノート
読み込み中…